Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 1, 2025

NCI-H2452

RRID:CVCL_1553
Type: Cell Line

Proper Citation

(RRID:CVCL_1553)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1553

Proper Citation: (RRID:CVCL_1553)

Sex: Male

Defining Citation: PMID:7695406, PMID:8806092, PMID:11030152, PMID:20164919, PMID:20215515, PMID:21245096, PMID:21642991, PMID:22460905, PMID:24926545, PMID:25485619, PMID:25877200, PMID:25902174, PMID:25984343, PMID:26011428, PMID:26589293, PMID:27397505, PMID:28553954, PMID:29681454, PMID:30894373, PMID:31068700, PMID:31395879, PMID:31803961, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: NCI-H2452

Synonyms: H2452, H-2452, NCIH2452

Cross References: CLO:CLO_0008077, EFO:EFO_0006680, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5946, BioSample:SAMN03471009, BioSample:SAMN10988138, BioSamples:SAMEA100910, cancercelllines:CVCL_1553, CCRID:3101HUMTCHu214, Cell_Model_Passport:SIDM00722, ChEMBL-Cells:CHEMBL3308580, ChEMBL-

Targets:CHEMBL1075540, CLS:300391, Cosmic:886392, Cosmic:908462, Cosmic:1032373, Cosmic:1481546, Cosmic:1522763, Cosmic:1541212, Cosmic:1571798, Cosmic:1749557, Cosmic:1963328, Cosmic:1995571, Cosmic:2474096, Cosmic:2758999, Cosmic:2759231, Cosmic-CLP:908462, DepMap:ACH-000092, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:908462, GEO:GSM726266, GEO:GSM827515, GEO:GSM850285, GEO:GSM887424, GEO:GSM888503, GEO:GSM1670234, LiGeA:CCLE_468, LINCS_LDP:LCL-1230, PharmacoDB:NCIH2452_1092_2019, PRIDE:PXD030304, Progenetix:CVCL_1553, PubChem_Cell_line:CVCL_1553, Wikidata:Q54907975

ID: CVCL_1553

Record Creation Time: 20250131T201501+0000

Record Last Update: 20250131T203141+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2452.

No alerts have been found for NCI-H2452.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Hirai S, et al. (2024) Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Molecular cancer therapeutics, 23(2), 212.

Kadariya Y, et al. (2024) Low Exposures to Amphibole or Serpentine Asbestos in Germline Bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment. Cancer research communications, 4(4), 1004.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Pandey GK, et al. (2023) Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell reports. Medicine, 4(2), 100915.

Maille E, et al. (2022) A defect of amphiregulin release predicted longer survival

independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial. International journal of cancer, 150(11), 1889.

Köferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. Cell reports, 39(2), 110636.

Sun R, et al. (2022) Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways. Translational lung cancer research, 11(4), 543.

Yang H, et al. (2021) NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers, 13(7).

Tan Y, et al. (2021) Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(4), 1200.

Barbarino M, et al. (2020) PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach. Journal of cellular and molecular medicine, 24(10), 5565.

Yang H, et al. (2020) Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers, 12(8).

Duong BTV, et al. (2020) A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma. EBioMedicine, 61, 103031.

Kolluri KK, et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife, 7.